United States: Pharmaceutical Antitrust 2017 | White & Case LLP International Law Firm, Global Law Practice
United States: Pharmaceutical Antitrust 2017

United States: Pharmaceutical Antitrust 2017

The past year has seen an increase in US case law developments in the area of pharmaceutical antitrust. This chapter focuses on the four types of pharmaceutical antitrust cases that have been most active:

  • US trial court and appellate court decisions adjudicating antitrust claims under the rule of reason test announced by the US Supreme Court in Federal Trade Commission v Actavis for innovator and generic settlements of pharmaceutical patent litigation involving alleged reverse payments or pay for delay;
  • so-called product-hopping antitrust claims against innovator pharmaceutical companies that introduce new versions of brand-name drugs facing generic competition;
  • alleged barriers to competition created when innovator companies deny generic companies access to sample product under REMS safety restrictions on distribution; and
  • challenges to pharmaceutical manufacturers' pricing practices.


Click here to download PDF.


This article was previously published by Global Competition Review in The Antitrust Review of the Americas 2017.

This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2016 White & Case LLP